Sat 7/21/2018 00:16 ET
DJIA25058.126.380.03%TELCO157.040.630.40%GOLD1231.907.880.64%Shanghai2769.203.320.12%
S&P 5002801.832.520.09%BANKS474.313.560.75%OIL68.130.110.16%BITCOIN7281.1652.420.72%
NASDAQ7820.205.470.07%PHARM518.010.830.16%US/EU1.170.000.26%Futures2804.750.500.02%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Nabriva Therapeutics AG - NBRV   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  
From: singhtelecom (Rep: 959)Date: 02/12/2018 07:43
Forum: Nabriva Therapeutics AG - Msg #26Thread #673990531 (Rec: 0)
VENBIO incresed 800% from 220k to 2 MILLION 1.announces that it has completed enrollment in its second lefamulin evaluation against pneumonia (LEAP 2) Phase 3 clinical trial. LEAP 2, which is designed to assess the efficacy and safety of oral lefamulin compared to oral moxifloxacin in adult patients with moderate community-acquired bacterial pneumonia (CABP), completed enrollment of 738 patients. The company anticipates topline clinical results from LEAP 2 to be available in the spring of 2018.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreNBRV: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.